A laboratory test that helps determine the likelihood of a patient with NSCLC benefitting from EGFR-TKI therapy, such as erlotinib, before determining the treatment path.

Intended for 2nd and 3rd line advanced non-small cell lung cancer(NSCLC) patients who are eligible for EGFR-TKI therapy.

Test correlates with survival outcomes after EGFR-TKI therapy

Identifying appropriate patients for 2nd and 3rd line therapy is critical to improving patient outcomes.

Leave a Reply

Your email address will not be published. Required fields are marked *